All Stories

  1. The role of extracellular vesicle-derived miRNA in the atherosclerotic burden

    Article • American Journal Of Pathology, September 2025, Elsevier

    Dr Massimiliano Ruscica

  2. Phytosterols and phytostanols in context: From physiology and pathophysiology to food supplementation and clinical practice

    Article • Pharmacological Research, April 2025, Elsevier

    Dr Massimiliano Ruscica

  3. Diagnostic Algorithm Using Multimodal Imaging for the Differential Diagnosis of Intra-Cardiac Masses

    Article • Journal of Clinical Medicine, January 2025, MDPI AG

    Dr Massimiliano Ruscica

  4. Long‐term fasting induces a remodelling of fatty acid composition in erythrocyte membranes

    Article • European Journal of Clinical Investigation, January 2025, Wiley

    Dr Massimiliano Ruscica

  5. Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor/tezacaftor/ivacaftor therapy

    Article • Journal of Cystic Fibrosis, January 2025, Elsevier

    Dr Massimiliano Ruscica

  6. Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?

    Article • Atherosclerosis Plus, December 2024, Elsevier

    Dr Massimiliano Ruscica

  7. Generalized arterial calcifications in a twin recipient treated with etidronate: description of a case report within a narrative review

    Article • Archives of Medical Science, October 2024, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  8. Hypercholesterolemia and inflammation—Cooperative cardiovascular risk factors

    Article • European Journal of Clinical Investigation, October 2024, Wiley

    Dr Massimiliano Ruscica

  9. HDL cholesterol efflux capacity and cholesterol loading capacity in long-term fasting: Evidence from a prospective, single-arm interventional study in healthy individuals

    Article • Atherosclerosis, October 2024, Elsevier

    Dr Massimiliano Ruscica

  10. Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study

    Article • Cardiovascular Diabetology, August 2024, Springer Science + Business Media

    Dr Massimiliano Ruscica

  11. Concordance between Coronary Artery Computed Tomography and Invasive Coronary Angiography in a Real-World Population with Suspected Chronic Coronary Syndrome

    Article • Diagnostics, August 2024, MDPI AG

    Dr Massimiliano Ruscica

  12. Correction: Ferri et al. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. J. Clin. Med. 2024, 13, 943

    Article • Journal of Clinical Medicine, August 2024, MDPI AG

    Dr Massimiliano Ruscica

  13. Anticancer Activity of Delta-Tocotrienol in Human Hepatocarcinoma: Involvement of Autophagy Induction

    Article • Cancers, July 2024, MDPI AG

    Dr Massimiliano Ruscica

  14. Imaging approaches in risk stratification of patients with coronary artery disease: a narrative review

    Article • Archives of Medical Science, June 2024, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  15. Prognostic Value of PCSK9 Levels in Premenopausal Women at Risk of Breast Cancer—Evidence from a 17-Year Follow-Up Study

    Article • Cancers, April 2024, MDPI AG

    Dr Massimiliano Ruscica

  16. Exploring the role of epicardial adipose-tissue-derived extracellular vesicles in cardiovascular diseases

    Article • iScience, April 2024, Elsevier

    Dr Massimiliano Ruscica

  17. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review

    Article • Journal of Clinical Medicine, February 2024, MDPI AG

    Dr Massimiliano Ruscica

  18. The ins and outs of lipoprotein(a) assay methods

    Article • Archives of Medical Science - Atherosclerotic Diseases, January 2024, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  19. Extracellular vesicles in cardiomyopathies: A narrative review

    Article • Heliyon, January 2024, Elsevier

    Dr Massimiliano Ruscica

  20. Right Heart Catheterization: An Antecubital Vein Approach to Reduce Fluoroscopy Time, Radiation Dose, and Guidewires Need

    Article • Journal of Clinical Medicine, August 2023, MDPI AG

    Dr Massimiliano Ruscica

  21. An association study of cyclase‐associated protein 2 and frailty

    Article • Aging Cell, August 2023, Wiley

    Dr Massimiliano Ruscica

  22. Induced myocardial ischemia in candidates to liver transplantation without evidence of heart disease

    Article • Annals of Medicine, July 2023, Taylor & Francis

    Dr Massimiliano Ruscica

  23. Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review

    Article • Frontiers in Cardiovascular Medicine, June 2023, Frontiers

    Dr Massimiliano Ruscica

  24. Protocol to evaluate the impact of murine MCT1-deficient CD8+ T cells on adipogenesis

    Article • STAR Protocols, June 2023, Elsevier

    Dr Massimiliano Ruscica

  25. Pollution from fine particulate matter and atherosclerosis: A narrative review

    Article • Environment International, May 2023, Elsevier

    Dr Massimiliano Ruscica

  26. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

    Article • Pharmacological Research, March 2023, Elsevier

    Professor Peter E. Penson, Dr Sonu Bhaskar, Professor Erkin Mirrakhimov, Prof. Maciej Banach, Dr Massimiliano Ruscica

  27. Lentilactobacillus kefiri SGL 13 and Andrographis paniculata alleviate dextran sulfate sodium induced colitis in mice

    Article • Frontiers in Nutrition, February 2023, Frontiers

    Dr Massimiliano Ruscica

  28. Editorial: The molecular mechanisms and therapeutic targets of atherosclerosis

    Article • Frontiers in Cardiovascular Medicine, January 2023, Frontiers

    Dr Massimiliano Ruscica

  29. Long-term fasting: Multi-system adaptations in humans (GENESIS) study–A single-arm interventional trial

    Article • Frontiers in Nutrition, November 2022, Frontiers

    Dr Massimiliano Ruscica

  30. PCSK9 Inhibition and Risk of Diabetes: Should We Worry?

    Article • Current Atherosclerosis Reports, November 2022, Springer Science + Business Media

    Dr Massimiliano Ruscica

  31. PCSK9 Confers Inflammatory Properties to Extracellular Vesicles Released by Vascular Smooth Muscle Cells

    Article • International Journal of Molecular Sciences, October 2022, MDPI AG

    Dr Massimiliano Ruscica

  32. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition

    Article • Expert Review of Clinical Pharmacology, October 2022, Taylor & Francis

    Dr Massimiliano Ruscica

  33. Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9

    Article • Pharmacological Research, October 2022, Elsevier

    Dr Massimiliano Ruscica

  34. Omega-3 and cardiovascular prevention – Is this still a choice?

    Article • Pharmacological Research, August 2022, Elsevier

    Dr Massimiliano Ruscica

  35. Bempedoic Acid: for Whom and When

    Article • Current Atherosclerosis Reports, July 2022, Springer Science + Business Media

    Dr Massimiliano Ruscica

  36. Synovial Fluid-Derived Extracellular Vesicles of Patients with Arthritides Contribute to Hippocampal Synaptic Dysfunctions and Increase with Mood Disorders Severity in Humans

    Article • Cells, July 2022, MDPI AG

    Dr Massimiliano Ruscica

  37. Effect of Bariatric Surgery on Flow-Mediated Vasodilation as a Measure of Endothelial Function: A Systematic Review and Meta-Analysis

    Article • Journal of Clinical Medicine, July 2022, MDPI AG

    Dr Massimiliano Ruscica

  38. Brain-Derived Neurotrophic Factor and Extracellular Vesicle-Derived miRNAs in an Italian Cohort of Individuals With Obesity: A Key to Explain the Link Between Depression and Atherothrombosis

    Article • Frontiers in Cardiovascular Medicine, July 2022, Frontiers

    Dr Massimiliano Ruscica

  39. Monocarboxylate transporter 1 deficiency impacts CD8+ T lymphocytes proliferation and recruitment to adipose tissue during obesity

    Article • iScience, June 2022, Elsevier

    Dr Massimiliano Ruscica

  40. HDL‐mediated reduction of cholesterol content inhibits the proliferation of prostate cancer cells induced by LDL: Role of ABCA1 and proteasome inhibition

    Article • BioFactors, May 2022, Wiley

    Dr Massimiliano Ruscica

  41. Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—Evidence from ApoE-/- Mice

    Article • International Journal of Molecular Sciences, May 2022, MDPI AG

    Dr Massimiliano Ruscica

  42. PCSK9 promotes arterial medial calcification

    Article • Atherosclerosis, April 2022, Elsevier

    Dr Massimiliano Ruscica

  43. The Role of High-Density Lipoprotein Cholesterol in 2022

    Article • Current Atherosclerosis Reports, March 2022, Springer Science + Business Media

    Dr Massimiliano Ruscica

  44. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications

    Article • Cardiovascular Research, March 2022, Oxford University Press (OUP)

    Prof. Maciej Banach, Dr Massimiliano Ruscica

  45. Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases

    Article • Journal of Clinical Medicine, February 2022, MDPI AG

    Dr Massimiliano Ruscica

  46. Research Progress on Natural Compounds Exerting an Antidepressant Effect through Anti-inflammatory

    Article • Current Medicinal Chemistry, February 2022, Bentham Science Publishers

    Xian Jun Loh, Dr Massimiliano Ruscica

  47. PCSK9 as a New Player in Cancer: New Opportunity or Red Herring?

    Article • Current Medicinal Chemistry, February 2022, Bentham Science Publishers

    Dr Massimiliano Ruscica

  48. Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity

    Article • Frontiers in Cardiovascular Medicine, January 2022, Frontiers

    Dr Massimiliano Ruscica

  49. Impact of Soy β-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells

    Article • Nutrients, December 2021, MDPI AG

    Dr Massimiliano Ruscica

  50. HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study

    Article • Journal of Clinical Medicine, December 2021, MDPI AG

    Dr Massimiliano Ruscica

  51. Lipoprotein(a): Knowns, unknowns and uncertainties

    Article • Pharmacological Research, November 2021, Elsevier

    Dr Massimiliano Ruscica

  52. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

    Article • Hepatology Communications, October 2021, Wolters Kluwer Health

    Dr Massimiliano Ruscica

  53. Cardiovascular complications of COVID-19: toward better understanding, diagnosis, monitoring and management

    Article • Expert Review of Anti-infective Therapy, August 2021, Taylor & Francis

    Dr Massimiliano Ruscica

  54. Proprotein Convertase Subtilisin/Kexin Type 9

    Article • American Journal Of Pathology, August 2021, Elsevier

    Dr Massimiliano Ruscica

  55. Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis—The IMPROVE Study

    Article • Biomedicines, July 2021, MDPI AG

    Dr Massimiliano Ruscica

  56. Effects of Statins on Renin–Angiotensin System

    Article • Journal of Cardiovascular Development and Disease, July 2021, MDPI AG

    Dr Massimiliano Ruscica

  57. Prognostic parameters of in‐hospital mortality in COVID‐19 patients—An Italian experience

    Article • European Journal of Clinical Investigation, June 2021, Wiley

    Dr Massimiliano Ruscica

  58. Reduction of Cardio-Metabolic Risk and Body Weight through a Multiphasic Very-Low Calorie Ketogenic Diet Program in Women with Overweight/Obesity: A Study in a Real-World Setting

    Article • Nutrients, May 2021, MDPI AG

    Dr Massimiliano Ruscica

  59. PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin

    Article • International Journal of Molecular Sciences, April 2021, MDPI AG

    Dr Massimiliano Ruscica

  60. The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity

    Article • Atherosclerosis, April 2021, Elsevier

    Dr Massimiliano Ruscica

  61. Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches

    Article • European Journal of Clinical Investigation, March 2021, Wiley

    Dr Massimiliano Ruscica

  62. Cardiovascular risk and testosterone – from subclinical atherosclerosis to lipoprotein function to heart failure

    Article • Reviews in Endocrine and Metabolic Disorders, February 2021, Springer Science + Business Media

    Dr Massimiliano Ruscica

  63. Effects of PM Exposure on the Methylation of Clock Genes in A Population of Subjects with Overweight or Obesity

    Article • International Journal of Environmental Research and Public Health, January 2021, MDPI AG

    Dr Massimiliano Ruscica

  64. Evaluation of Transthoracic Echocardiography in the Assessment of Atherosclerosis of the Left Main Coronary Artery: Comparison with Optical Frequency Domain Imaging (a Pilot Study)

    Article • Journal of Clinical Medicine, January 2021, MDPI AG

    Dr Massimiliano Ruscica

  65. Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9

    Article • American Journal Of Pathology, November 2020, Elsevier

    Dr Massimiliano Ruscica

  66. Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients

    Article • Nutrition Metabolism and Cardiovascular Diseases, November 2020, Elsevier

    Dr Massimiliano Ruscica

  67. Impact of Phyllantus niruri and Lactobacillus amylovorus SGL 14 in a mouse model of dietary hyperoxaluria

    Article • Beneficial Microbes, October 2020, Wageningen Academic Publishers

    Dr Massimiliano Ruscica

  68. PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma

    Article • Journal of Clinical Medicine, September 2020, MDPI AG

    Dr Massimiliano Ruscica

  69. The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients

    Article • Journal of Clinical Medicine, September 2020, MDPI AG

    Dr Massimiliano Ruscica

  70. Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study

    Article • Atherosclerosis, September 2020, Elsevier

    Dr Mauro AMATO, Dr Massimiliano Ruscica

  71. Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach

    Article • Journal of Clinical Medicine, July 2020, MDPI AG

    Dr Massimiliano Ruscica

  72. Unravelling the health effects of fasting: a long road from obesity treatment to healthy life span increase and improved cognition

    Article • Annals of Medicine, June 2020, Taylor & Francis

    Dr Massimiliano Ruscica

  73. PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation

    Article • Mediators of Inflammation, June 2020, Wiley

    Dr Massimiliano Ruscica

  74. The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients

    Article • European Respiratory Journal, May 2020, European Respiratory Society (ERS)

    Marco Vicenzi, Dr Massimiliano Ruscica

  75. Naturally Occurring PCSK9 Inhibitors

    Article • Nutrients, May 2020, MDPI AG

    Dr Massimiliano Ruscica

  76. HDL therapy today: from atherosclerosis, to stent compatibility to heart failure

    Article • Annals of Medicine, November 2019, Taylor & Francis

    Dr Massimiliano Ruscica, Prof Roberto Giovannoni

  77. Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study

    Article • European Journal of Preventive Cardiology, October 2019, SAGE Publications

    Dr Arrigo FG CICERO, Dr Massimiliano Ruscica

  78. Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis

    Article • International Journal of Molecular Sciences, September 2019, MDPI AG

    Dr Massimiliano Ruscica

  79. A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES

    Article • Pharmacological Research, August 2019, Elsevier

    Dr Massimiliano Ruscica

  80. PCSK9 inhibition and inflammation: A narrative review

    Article • Atherosclerosis, July 2019, Elsevier

    Dr Massimiliano Ruscica

  81. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, July 2019, Elsevier

    Dr Massimiliano Ruscica

  82. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

    Article • Cardiovascular Diabetology, June 2019, Springer Science + Business Media

    Dr Massimiliano Ruscica

  83. Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake

    Article • Nutrition Metabolism and Cardiovascular Diseases, June 2019, Elsevier

    Dr Massimiliano Ruscica

  84. Can we further optimize statin therapy to increase tolerability?

    Article • Expert Opinion on Drug Discovery, May 2019, Taylor & Francis

    Dr Massimiliano Ruscica

  85. PCSK9 in HIV infection: New opportunity or red herring?

    Article • Atherosclerosis, May 2019, Elsevier

    Dr Massimiliano Ruscica

  86. Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

    Article • Drugs, April 2019, Springer Science + Business Media

    Dr Massimiliano Ruscica

  87. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients

    Article • Journal of Lipid Research, March 2019, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Massimiliano Ruscica

  88. PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies

    Article • European Journal of Preventive Cardiology, March 2019, SAGE Publications

    Dr Massimiliano Ruscica

  89. High-Density Lipoprotein Function Is Reduced in Patients Affected by Genetic or Idiopathic Hypogonadism

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2019, Endocrine Society

    Dr Massimiliano Ruscica

  90. Deciphering the role of V200A and N291S mutations leading to LPL deficiency

    Article • Atherosclerosis, March 2019, Elsevier

    Dr Massimiliano Ruscica

  91. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials

    Article • Expert Opinion on Pharmacotherapy, February 2019, Taylor & Francis

    Dr Massimiliano Ruscica, Prof. Maciej Banach

  92. Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study

    Article • Nutrition Journal, February 2019, Springer Science + Business Media

    Dr Massimiliano Ruscica

  93. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents

    Article • European Journal of Preventive Cardiology, February 2019, SAGE Publications

    Dr Massimiliano Ruscica

  94. Resveratrol and cognitive decline: a clinician perspective

    Article • Archives of Medical Science, January 2019, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  95. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals

    Article • European Journal of Preventive Cardiology, November 2018, SAGE Publications

    Dr Massimiliano Ruscica

  96. Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists

    Article • Atherosclerosis, November 2018, Elsevier

    Dr Massimiliano Ruscica

  97. Left main coronary wall thickness correlates with the carotid intima media thickness and may provide a new marker of cardiovascular risk

    Article • European Journal of Preventive Cardiology, October 2018, SAGE Publications

    Dr Massimiliano Ruscica

  98. Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status

    Article • Journal of Neurology, October 2018, Springer Science + Business Media

    Dr Massimiliano Ruscica

  99. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients

    Article • European Journal of Preventive Cardiology, July 2018, SAGE Publications

    Dr Massimiliano Ruscica

  100. Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes?

    Article • Annals of Medicine, July 2018, Taylor & Francis

    Dr Massimiliano Ruscica

  101. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor

    Article • European Heart Journal, July 2018, Oxford University Press (OUP)

    Dr Massimiliano Ruscica

  102. Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials

    Article • Journal of Clinical Lipidology, May 2018, Elsevier

    Prof. Maciej Banach, Dr Massimiliano Ruscica

  103. PPAR Agonists and Metabolic Syndrome: An Established Role?

    Article • International Journal of Molecular Sciences, April 2018, MDPI AG

    Dr Massimiliano Ruscica

  104. Appropriateness of statin prescription in the elderly

    Article • European Journal of Internal Medicine, April 2018, Elsevier

    Dr Massimiliano Ruscica

  105. Influence of body variables in the development of metabolic syndrome—A long term follow-up study

    Article • PLOS One, February 2018, PLOS

    Dr Massimiliano Ruscica

  106. High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation

    Article • Scientific Reports, February 2018, Springer Science + Business Media

    Dr Massimiliano Ruscica

  107. PCSK9 induces a pro-inflammatory response in macrophages

    Article • Scientific Reports, February 2018, Springer Science + Business Media

    Dr Massimiliano Ruscica

  108. PCSK9 as a Positive Modulator of Platelet Activation

    Article • Journal of the American College of Cardiology, February 2018, Elsevier

    Dr Massimiliano Ruscica

  109. Present therapeutic role of cholesteryl ester transfer protein inhibitors

    Article • Pharmacological Research, February 2018, Elsevier

    Dr Massimiliano Ruscica

  110. PCSK9 antagonists and inflammation

    Article • Atherosclerosis, January 2018, Elsevier

    Dr Massimiliano Ruscica

  111. Nutraceutical approaches to metabolic syndrome

    Article • Annals of Medicine, August 2017, Taylor & Francis

    Dr Massimiliano Ruscica

  112. Bococizumab for the treatment of hypercholesterolaemia

    Article • Expert Opinion on Biological Therapy, May 2017, Taylor & Francis

    Dr Massimiliano Ruscica

  113. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions

    Article • Nutrition Metabolism and Cardiovascular Diseases, May 2017, Elsevier

    Dr Massimiliano Ruscica

  114. PPAR-α agonists are still on the rise: an update on clinical and experimental findings

    Article • Expert Opinion on Investigational Drugs, April 2017, Taylor & Francis

    Dr Massimiliano Ruscica

  115. Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial

    Article • Zeitschrift für Ernährungswissenschaft, October 2016, Springer Science + Business Media

    Dr Massimiliano Ruscica

  116. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence

    Article • Translational Research, July 2016, Elsevier

    Dr Massimiliano Ruscica

  117. Increased circulating adiponectin in males with chronic HCV hepatitis

    Article • European Journal of Internal Medicine, October 2015, Elsevier

    Dr Massimiliano Ruscica

  118. Free and bound plasma leptin in anorexia nervosa patients during a refeeding program

    Article • Endocrine, April 2015, Springer Science + Business Media

    Dr Massimiliano Ruscica

  119. Menstrual and reproductive history and use of exogenous sex hormones and risk of thyroid cancer among women: a meta-analysis of prospective studies

    Article • Cancer Causes & Control, March 2015, Springer Science + Business Media

    Dr Massimiliano Ruscica

  120. Risk identification and possible countermeasures for muscle adverse effects during statin therapy

    Article • European Journal of Internal Medicine, March 2015, Elsevier

    Dr Massimiliano Ruscica

  121. Changes in Stress Hormones and Metabolism During a 105-Day Simulated Mars Mission

    Article • Aviation Space and Environmental Medicine, August 2014, Aerospace Medical Association

    Dr Massimiliano Ruscica

  122. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance

    Article • European Journal of Clinical Investigation, June 2014, Wiley

    Luca Valenti, Dr Massimiliano Ruscica

  123. Statin therapy and related risk of new-onset type 2 diabetes mellitus

    Article • European Journal of Internal Medicine, June 2014, Elsevier

    Dr Massimiliano Ruscica

  124. Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: Effect of mono- and bi-specific somatostatin analogs on cell growth

    Article • Molecular and Cellular Endocrinology, February 2014, Elsevier

    Dr Massimiliano Ruscica

  125. In VitroChronic Administration of ERbeta Selective Ligands and Prostate Cancer Cell Growth: Hypotheses on the Selective Role of 3beta-Adiol in AR-Positive RV1 Cells

    Article • BioMed Research International, January 2014, Hindawi Publishing Corporation

    Dr Massimiliano Ruscica

  126. Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus

    Article • Journal of Clinical Lipidology, January 2014, Elsevier

    Dr Massimiliano Ruscica

  127. Antiproliferative activity on human prostate carcinoma cell lines of new peptidomimetics containing the spiroazepinoindolinone scaffold

    Article • Bioorganic & Medicinal Chemistry, September 2013, Elsevier

    Dr Massimiliano Ruscica

  128. Dietary Iron Overload Induces Visceral Adipose Tissue Insulin Resistance

    Article • American Journal Of Pathology, June 2013, Elsevier

    Dr Massimiliano Ruscica

  129. Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression

    Article • Current Molecular Medicine, April 2013, Bentham Science Publishers

    Dr Massimiliano Ruscica

  130. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients

    Article • The Aging Male, March 2013, Taylor & Francis

    Dr Massimiliano Ruscica

  131. GC–MS profiling of the phytochemical constituents of the oleoresin from Copaifera langsdorffii Desf. and a preliminary in vivo evaluation of its antipsoriatic effect

    Article • International Journal of Pharmaceutics, January 2013, Elsevier

    Dr Fabrizio Gelmini, Dr Massimiliano Ruscica

  132. The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls

    Article • BMC Gastroenterology, August 2012, Springer Science + Business Media

    Dr Massimiliano Ruscica

  133. Parthenolide Inhibits the LPS-induced Secretion of IL-6 and TNF-α and NF-κB Nuclear Translocation in BV-2 Microglia

    Article • Phytotherapy Research, February 2012, Wiley

    Dr Massimiliano Ruscica

  134. Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients

    Article • Muscle & Nerve, January 2012, Wiley

    Dr Massimiliano Ruscica

  135. Prognostic Effect of Circulating Adiponectin in a Randomized 2 × 2 Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women at Risk for Breast Cancer

    Article • Journal of Clinical Oncology, January 2012, American Society of Clinical Oncology (ASCO)

    Dr Massimiliano Ruscica

  136. Metabolic Syndrome, Adipokines and Hormonal Factors in Pharmacologically Untreated Adult Elderly Subjects from the Brisighella Heart Study Historical Cohort

    Article • Obesity Facts, January 2012, Karger Publishers

    Dr Arrigo FG CICERO, Dr Massimiliano Ruscica

  137. Adiponectin Interactions in Bone and Cartilage Biology and Disease

    Article • January 2012, Elsevier

    Dr Massimiliano Ruscica

  138. Corrigendum to “Regulation of prostate cancer cell proliferation by somatostatin receptor activation” [Mol. Cell. Endocrinol. 315 (1–2) (2010) 254–262]

    Article • Molecular and Cellular Endocrinology, July 2011, Elsevier

    Dr Massimiliano Ruscica

  139. Adipokines and Sexual Hormones Associated with the Components of the Metabolic Syndrome in Pharmacologically Untreated Subjects: Data from the Brisighella Heart Study

    Article • International Journal of Endocrinology, January 2011, Hindawi Publishing Corporation

    Dr Arrigo FG CICERO, Dr Massimiliano Ruscica

  140. Adipokine actions on cartilage homeostasis

    Article • January 2011, Elsevier

    Dr Massimiliano Ruscica

  141. Erratum to “The natural antioxidant alpha-lipoic acid induces p27Kip1-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells” [Eur. J. Pharmacol. 641 (2010) 29-34]

    Article • European Journal of Pharmacology, January 2011, Elsevier

    Dr Massimiliano Ruscica

  142. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines

    Article • Journal of Endocrinology, September 2010, Bioscientifica

    Dr Massimiliano Ruscica

  143. The natural antioxidant alpha-lipoic acid induces p27Kip1-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells

    Article • European Journal of Pharmacology, September 2010, Elsevier

    Dr Massimiliano Ruscica

  144. Pharmacokinetics of orally administered melatonin in critically ill patients

    Article • Journal of Pineal Research, March 2010, Wiley

    Dr Massimiliano Ruscica

  145. Regulation of prostate cancer cell proliferation by somatostatin receptor activation

    Article • Molecular and Cellular Endocrinology, February 2010, Elsevier

    Dr Massimiliano Ruscica

  146. Leptin, Ciliary Neurotrophic Factor, Leukemia Inhibitory Factor and Interleukin- 6: Class-I Cytokines Involved in the Neuroendocrine Regulation of the Reproductive Function

    Article • Current Protein and Peptide Science, December 2009, Bentham Science Publishers

    Dr Massimiliano Ruscica

  147. Free insulin-like growth factor (IGF)-1 and IGF-binding proteins-2 and -3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients

    Article • European Journal of Neurology, October 2009, Wiley

    Dr Massimiliano Ruscica

  148. Feeding Behavior in Mammals Including Humans

    Article • Annals of the New York Academy of Sciences, April 2009, Wiley

    Dr Massimiliano Ruscica

  149. Effect of Fenretinide and Low-Dose Tamoxifen on Insulin Sensitivity in Premenopausal Women at High Risk for Breast Cancer

    Article • Cancer Research, November 2008, American Association for Cancer Research (AACR)

    Dr Massimiliano Ruscica

  150. Total, free and bound leptin and thyroid function in elderly women with different body weights

    Article • Clinical Endocrinology, June 2008, Wiley

    Dr Massimiliano Ruscica

  151. Cholinergic regulation of neuropeptide Y synthesis and release in human neuroblastoma cells

    Article • Peptides, March 2008, Elsevier

    Dr Massimiliano Ruscica

  152. Leukemia Inhibitory Factor Induces the Chemomigration of Immortalized Gonadotropin-Releasing Hormone Neurons through the Independent Activation of the Janus Kinase/Signal Transducer and Activator of Transcription 3, Mitogen-Activated Protein Kinase/Ext...

    Article • Molecular Endocrinology, May 2007, Endocrine Society

    Dr Massimiliano Ruscica

  153. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas

    Article • Clinical Endocrinology, March 2007, Wiley

    Marta Korbonits, Dr Massimiliano Ruscica

  154. Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer

    Article • Peptides, February 2007, Elsevier

    Dr Massimiliano Ruscica

  155. Hypothalamic Neuropeptide Systems as Targets for Potential Anti-Obesity Drugs

    Article • Mini-Reviews in Medicinal Chemistry, January 2007, Bentham Science Publishers

    Dr Massimiliano Ruscica

  156. Is ghrelin a signal of decreased fat-free mass in elderly subjects?

    Article • European Journal of Endocrinology, August 2006, Bioscientifica

    Dr Massimiliano Ruscica

  157. Activation of the Y1 Receptor by Neuropeptide Y Regulates the Growth of Prostate Cancer Cells

    Article • Endocrinology, March 2006, Endocrine Society

    Dr Massimiliano Ruscica

  158. Expression of Functional Ciliary Neurotrophic Factor Receptors in Immortalized Gonadotrophin-Releasing Hormone-Secreting Neurones

    Article • Journal of Neuroendocrinology, May 2005, Wiley

    Dr Massimiliano Ruscica

  159. Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference

    Article • Clinical Endocrinology, February 2005, Wiley

    Dr Massimiliano Ruscica

  160. Free and bound leptin in prepubertal children with Down's syndrome and different degrees of adiposity

    Article • European Journal of Clinical Nutrition, May 2004, Springer Science + Business Media

    Dr Massimiliano Ruscica

  161. Modulatory Actions of Neuropeptide Y on Prostate Cancer Growth: Role of MAP Kinase/ERK 1/2 Activatio

    Article • Springer Science + Business Media

    Dr Massimiliano Ruscica